[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Famotidine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be increased when used in combination with Famotidine.]
[L01BB02, mercaptopurine, The excretion of Mercaptopurine can be decreased when combined with Famotidine.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Famotidine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Famotidine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Famotidine.]
[B01AE07, dabigatran etexilate, Famotidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03BA03, testosterone, The excretion of Famotidine can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tetrabenazine.]
[S03AA02, tetracycline, The excretion of Famotidine can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Famotidine.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Famotidine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Famotidine.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Famotidine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eribulin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Thiothixene.]
[B03AB03, sodium ironedetate, Famotidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Famotidine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Famotidine.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Famotidine.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Famotidine.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Famotidine.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Famotidine.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Famotidine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Famotidine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Famotidine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Famotidine.]
[J05AG05, rilpivirine, Famotidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Famotidine.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Famotidine.]
[J05AF01, zidovudine, The excretion of Famotidine can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Zuclopenthixol.]
[J05AE02, indinavir, Famotidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Famotidine.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ziprasidone.]
[N02BA01, aspirin, The excretion of Famotidine can be decreased when combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Tolterodine.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Famotidine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Famotidine.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Famotidine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Famotidine.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Famotidine.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mirabegron.]
[L01EA04, bosutinib, Famotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA31, teriflunomide, The excretion of Famotidine can be decreased when combined with Teriflunomide.]
[J05AE04, nelfinavir, Famotidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Famotidine.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Famotidine.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Famotidine.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Famotidine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pasireotide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bencyclane.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Famotidine.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Famotidine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Famotidine.]
[L01EC02, dabrafenib, Famotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Famotidine.]
[B03AB04, ferric hydroxide, Famotidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AJ03, dolutegravir, The excretion of Famotidine can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bepridil.]
[C02KX05, riociguat, Famotidine can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Famotidine.]
[V03AE05, sucroferric oxyhydroxide, Famotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Famotidine.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Famotidine.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Famotidine.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Famotidine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Famotidine.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib.]
[A03BA03, hyoscyamine, Famotidine may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Famotidine.]
[N07XX08, tafamidis, The excretion of Famotidine can be decreased when combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Olodaterol.]
[V03AE01, polystyrene sulfonate, The therapeutic efficacy of Tolevamer can be decreased when used in combination with Famotidine.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eliglustat.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Famotidine.]
[V03AE08, ferric citrate, Famotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Famotidine.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Famotidine.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Famotidine.]
[L01EF01, palbociclib, The absorption of Palbociclib can be decreased when combined with Famotidine.]
[L01EX08, lenvatinib, The excretion of Famotidine can be decreased when combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Famotidine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivabradine.]
[J05AP06, asunaprevir, Famotidine can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07DA06, eluxadoline, The excretion of Eluxadoline can be decreased when combined with Famotidine.]
[A02BC03, lansoprazole, The excretion of Famotidine can be decreased when combined with Lansoprazole.]
[J02AC05, isavuconazole, Famotidine can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF13, tenofovir alafenamide, The excretion of Tenofovir alafenamide can be decreased when combined with Famotidine.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Famotidine.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Famotidine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Famotidine.]
[C03CA02, bumetanide, The excretion of Famotidine can be decreased when combined with Bumetanide.]
[N01BB01, bupivacaine, The metabolism of Levobupivacaine can be decreased when combined with Famotidine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Buserelin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Famotidine.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Famotidine.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Famotidine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Famotidine.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Famotidine.]
[N06BC01, caffeine, The metabolism of Caffeine can be decreased when combined with Famotidine.]
[J01XX08, linezolid, The excretion of Famotidine can be decreased when combined with Linezolid.]
[J05AE09, tipranavir, Famotidine can cause a decrease in the absorption of Tipranavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Delafloxacin.]
[D01AC10, bifonazole, Famotidine can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Famotidine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Vorinostat.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Famotidine.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Efavirenz.]
[R03BA02, budesonide, Famotidine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AX18, letermovir, The excretion of Famotidine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The metabolism of Capsaicin can be decreased when combined with Famotidine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.]
[C09AA01, captopril, Famotidine can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Macimorelin.]
[L02BB05, apalutamide, The excretion of Famotidine can be decreased when combined with Apalutamide.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Famotidine.]
[B02BX08, avatrombopag, The excretion of Famotidine can be decreased when combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Famotidine.]
[J01DD13, cefpodoxime, Famotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Famotidine.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Famotidine.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Stiripentol can be decreased when combined with Famotidine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Famotidine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Famotidine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Inotersen.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Famotidine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cilostazol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Famotidine.]
[J01DC04, cefaclor, The excretion of Famotidine can be decreased when combined with Cefaclor.]
[J01DB05, cefadroxil, The excretion of Famotidine can be decreased when combined with Cefadroxil.]
[J01DC03, cefamandole, The excretion of Famotidine can be decreased when combined with Cefamandole.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Famotidine.]
[J01DD12, cefoperazone, The excretion of Famotidine can be decreased when combined with Cefoperazone.]
[J01DD01, cefotaxime, The excretion of Famotidine can be decreased when combined with Cefotaxime.]
[J01DC07, cefotiam, The excretion of Famotidine can be decreased when combined with Cefotiam.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cicletanine.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Famotidine.]
[J01DD04, ceftriaxone, The excretion of Famotidine can be decreased when combined with Ceftriaxone.]
[S01AA27, cefuroxime, Famotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Famotidine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Entrectinib.]
[N07XX11, pitolisant, Famotidine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Famotidine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Famotidine.]
[J01DB01, cephalexin, The excretion of Famotidine can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Famotidine.]
[J01DB03, cephalothin, The excretion of Famotidine can be decreased when combined with Cefalotin.]
[J01DB09, cephradine, The excretion of Cefradine can be decreased when combined with Famotidine.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Famotidine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gatifloxacin.]
[J05AE05, amprenavir, Famotidine can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Famotidine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Famotidine.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Famotidine.]
[C01BD07, dronedarone, The excretion of Famotidine can be decreased when combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorcyclizine.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Famotidine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ebastine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Famotidine.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Famotidine.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Relugolix.]
[J05AJ04, cabotegravir, The excretion of Famotidine can be decreased when combined with Cabotegravir.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Famotidine.]
[V08CA07, ferric ammonium citrate, Famotidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Famotidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Famotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Famotidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Famotidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Famotidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Famotidine can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Famotidine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flumequine.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Famotidine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Famotidine.]
[B03AB10, ferric maltol, Famotidine can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The excretion of Famotidine can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinoxacin.]
[L01XX73, sotorasib, The therapeutic efficacy of Sotorasib can be decreased when used in combination with Famotidine.]
[L01EN03, infigratinib, The serum concentration of Infigratinib can be decreased when it is combined with Famotidine.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Famotidine.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Famotidine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clemastine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Famotidine.]
[N01BB10, levobupivacaine, The metabolism of Levobupivacaine can be decreased when combined with Famotidine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Famotidine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Famotidine.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Famotidine.]
[J02AC06, oteseconazole, Famotidine can cause a decrease in the absorption of Oteseconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Clozapine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cocaine.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Famotidine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desflurane.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desloratadine.]
[J05AF09, emtricitabine, The excretion of Emtricitabine can be decreased when combined with Famotidine.]
[J02AC02, itraconazole, Famotidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AD03, acyclovir, The excretion of Famotidine can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Posaconazole.]
[A02BC05, esomeprazole, The excretion of Famotidine can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Famotidine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocabastine.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lomefloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Adenosine.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the sedative and stimulatory activities of Famotidine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cyclizine.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Melperone.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Famotidine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Famotidine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Famotidine.]
[C10AA07, rosuvastatin, The excretion of Rosuvastatin can be decreased when combined with Famotidine.]
[S01XA21, cysteamine, The bioavailability of Cysteamine can be decreased when combined with Famotidine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Famotidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Famotidine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Famotidine.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Famotidine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Famotidine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Famotidine.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Solifenacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desipramine.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Famotidine.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Famotidine.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Famotidine.]
[L01EB01, gefitinib, Famotidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the sedative and stimulatory activities of Famotidine.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Famotidine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Famotidine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Famotidine.]
[S01BC03, diclofenac, The excretion of Famotidine can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Famotidine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pinaverium.]
[L01EB02, erlotinib, Famotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A08AA03, diethylpropion, Diethylpropion may decrease the sedative and stimulatory activities of Famotidine.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Famotidine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Famotidine.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Famotidine.]
[J05AE08, atazanavir, Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Famotidine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dimenhydrinate.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Famotidine.]
[G02AD02, dinoprostone, The excretion of Famotidine can be decreased when combined with Dinoprostone.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Famotidine.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Diphenhydramine.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Famotidine.]
[N06BA11, dexmethylphenidate, The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Famotidine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Cisapride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Famotidine.]
[N07XX02, riluzole, The metabolism of Riluzole can be decreased when combined with Famotidine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Famotidine.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The metabolism of Ropivacaine can be decreased when combined with Famotidine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Famotidine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sunitinib.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine.]
[J05AE07, fosamprenavir, Famotidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Domperidone.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Famotidine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxepin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Famotidine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Droperidol.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Talinolol.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Famotidine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The excretion of Famotidine can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Famotidine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terodiline.]
[C09AA02, enalapril, The excretion of Famotidine can be decreased when combined with Enalapril.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Famotidine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Toremifene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Famotidine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Famotidine.]
[S01EA01, epinephrine, The serum concentration of Epinephrine can be increased when it is combined with Famotidine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Famotidine.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Famotidine.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Famotidine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Famotidine.]
[N03AG01, valproic acid, The excretion of Valproic acid can be decreased when combined with Famotidine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Erythromycin.]
[A02BC02, pantoprazole, The excretion of Famotidine can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Famotidine.]
[G03CA03, estradiol, The excretion of Estradiol can be decreased when combined with Famotidine.]
[G03CA57, estrogens, conjugated (USP), The excretion of Famotidine can be decreased when combined with Conjugated estrogens.]
[C01CA15, gepefrine, Gepefrine may decrease the sedative and stimulatory activities of Famotidine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Famotidine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Famotidine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Famotidine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Famotidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Famotidine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Famotidine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.]
[C10AA03, pravastatin, The excretion of Famotidine can be decreased when combined with Pravastatin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pipemidic acid.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Famotidine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Famotidine.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Famotidine.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Famotidine.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Famotidine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Famotidine.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Famotidine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flupentixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Famotidine.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Famotidine.]
[J05AE10, darunavir, Famotidine can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C03CA01, furosemide, The excretion of Famotidine can be decreased when combined with Furosemide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Famotidine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Gallopamil.]
[S01AD09, ganciclovir, The excretion of Famotidine can be decreased when combined with Ganciclovir.]
[C10AB04, gemfibrozil, The excretion of Famotidine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Degarelix.]
[L01EA02, dasatinib, Famotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Famotidine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lapatinib.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Famotidine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Famotidine.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Famotidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quetiapine.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Famotidine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Famotidine.]
[A07EC02, mesalamine, Famotidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Famotidine.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Famotidine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Hydroxyzine.]
[M05BA07, risedronic acid, Famotidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Famotidine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Terlipressin.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be increased when it is combined with Famotidine.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Famotidine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Famotidine.]
[S01BC01, indomethacin, The excretion of Famotidine can be decreased when combined with Indomethacin.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Famotidine.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Famotidine.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Famotidine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Famotidine.]
[L01XX35, anagrelide, The metabolism of Anagrelide can be decreased when combined with Famotidine.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Famotidine.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Famotidine.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Famotidine.]
[J02AB02, ketoconazole, Famotidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Famotidine.]
[M02AA10, ketoprofen, The excretion of Famotidine can be decreased when combined with Ketoprofen.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nalidixic acid.]
[N04BB01, amantadine, The serum concentration of Amantadine can be increased when it is combined with Famotidine.]
[S02DA01, lidocaine, The metabolism of Lidocaine can be decreased when combined with Famotidine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Lidoflazine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Loperamide.]
[L01EA03, nilotinib, Famotidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Maprotiline.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Famotidine.]
[N05CH01, melatonin, The excretion of Famotidine can be decreased when combined with Melatonin.]
[N06DX01, memantine, Famotidine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[C01CA11, mephentermine, Mephentermine may decrease the sedative and stimulatory activities of Famotidine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Famotidine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone.]
[A10BA02, metformin, The serum concentration of Metformin can be increased when it is combined with Famotidine.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methadone.]
[N06BA03, methamphetamine, Metamfetamine may decrease the sedative and stimulatory activities of Famotidine.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Famotidine.]
[J01XX05, methenamine, The therapeutic efficacy of Methenamine can be decreased when used in combination with Famotidine.]
[L01BA04, pemetrexed, Famotidine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[L04AX03, methotrexate, The excretion of Famotidine can be decreased when combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methotrimeprazine.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Famotidine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Famotidine.]
[N06BA04, methylphenidate, The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.]
[G03EK01, methyltestosterone, The excretion of Famotidine can be increased when combined with Methyltestosterone.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Famotidine.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Famotidine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Famotidine.]
[S02AA13, miconazole, Famotidine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Famotidine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mifepristone.]
[J01AA08, minocycline, The excretion of Famotidine can be decreased when combined with Minocycline.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Famotidine.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Amitriptyline.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Famotidine.]
[L01EX03, pazopanib, Famotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA06, mycophenolic acid, Famotidine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AJ01, raltegravir, Famotidine can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Famotidine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Famotidine.]
[C07AA12, nadolol, The excretion of Nadolol can be decreased when combined with Famotidine.]
[N04BC04, ropinirole, The metabolism of Ropinirole can be decreased when combined with Famotidine.]
[N06BA01, amphetamine, Amphetamine may decrease the sedative and stimulatory activities of Famotidine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Famotidine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Iloperidone.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Famotidine.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Famotidine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nimodipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Nitrendipine.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Famotidine.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Famotidine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Norfloxacin.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Famotidine.]
[H01CB02, octreotide, Famotidine can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ofloxacin.]
[C01AC01, ouabain, The excretion of Famotidine can be decreased when combined with Ouabain.]
[V08CB01, ferumoxsil, Famotidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxolinic acid.]
[S01AA04, oxytetracycline, The excretion of Famotidine can be decreased when combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.]
[V04CH30, 4-aminohippuric acid, The excretion of Famotidine can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Famotidine.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Penfluridol.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Famotidine.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Famotidine.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Famotidine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Famotidine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Pheniramine.]
[A08AA01, phentermine, Phentermine may decrease the sedative and stimulatory activities of Famotidine.]
[M02AA01, phenylbutazone, The excretion of Famotidine can be decreased when combined with Phenylbutazone.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levofloxacin.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Famotidine.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Famotidine.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Famotidine.]
[J05AE01, saquinavir, Famotidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01BC06, piroxicam, The excretion of Famotidine can be decreased when combined with Piroxicam.]
[J01DD16, cefditoren, The serum concentration of Cefditoren can be decreased when it is combined with Famotidine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Grepafloxacin.]
[J05AG02, delavirdine, Famotidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Famotidine.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Famotidine.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Famotidine.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Famotidine.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Famotidine.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Famotidine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Primaquine.]
[M04AB01, probenecid, The excretion of Famotidine can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Probucol.]
[C01BA02, procainamide, The excretion of Procainamide can be decreased when combined with Famotidine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Propafenone.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Famotidine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Famotidine.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Famotidine.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Famotidine.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the sedative and stimulatory activities of Famotidine.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Famotidine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Mepyramine.]
[C01BA01, quinidine, The excretion of Famotidine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Famotidine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Famotidine.]
[J04AB02, rifampin, Famotidine can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Roxithromycin.]
[S01BC08, salicylic acid, The excretion of Famotidine can be decreased when combined with Salicylic acid.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Famotidine.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sotalol.]
[H02CA04, levoketoconazole, Famotidine can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.]
